Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax

NEW YORK, October 31, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On October 28, 2013, Biogen Idec Inc. (Biogen Idec) released its Q3 2013 results. Biogen Idec registered Q3 2013 revenues of $1.8 billion, up 31.9% YoY. According to Biogen Idec, revenues were primarily driven by TECFIDERA (dimethyl fumarate), which is now the leading oral MS therapy in the US and accounted for $286 million in Q3 2013 revenues. Net income attributable to the Company was $487.6 million or $2.05 per diluted share, compared to $398.4 million or $1.67 per diluted share in Q3 2012. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB]

--

Alexion Pharmaceuticals, Inc. Research Report

On October 24, 2013, Alexion Pharmaceuticals, Inc. (Alexion) released its Q3 2013 results. Alexion registered net product sales of $400.4 million, compared to $294.1 million in Q3 2012. Alexion posted net income of $93.8 million or $0.47 per diluted share, compared to $294.1 million or $0.46 per diluted share in Q3 2012. Commenting on the results, Leonard Bell, M.D., CEO of Alexion, said, "In the third quarter, we continued our strong and ongoing global performance with Soliris in PNH and were pleased to provide Soliris to a steadily growing number of new patients with aHUS in the United States as well as an increasing number of patients with aHUS in Europe. In addition, we were pleased to receive our aHUS approval in Japan." Bell continued, "Key pipeline initiatives, including our asfotase alfa program in HPP, our Soliris programs in kidney transplant and our cPMP replacement therapy program, reached new milestones in Q3. In Q4, we are further expanding our commercial and clinical initiatives as we prepare for further growth in 2014." The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4619_ALXN]

--

Medivation, Inc. Research Report

On October 28, 2013, Medivation, Inc. (Medivation) announced that it will release its Q3 2013 results after the markets close on November 12, 2013. Medivation reported that the release will be followed by its Q3 2013 conference call on the same day at 4:30 p.m. ET. The Company stated that the live conference will be accessible through its Investor Relations website. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4277_MDVN]

--

BioMarin Pharmaceutical Inc. Research Report

On October 24, 2013, BioMarin Pharmaceutical Inc. (BioMarin) released its Q3 2013 results. BioMarin registered total revenues of $136.9 million, an increase of 6.9% YoY. The Company posted net loss of $53.0 million in Q3 2013, compared to net loss of $5.4 million in Q3 2012. BioMarin reported diluted loss per share of $0.38 in Q3 2013, compared to diluted loss per share of $0.04 in Q3 2012. Jean-Jacques Bienaimé, CEO of BioMarin, stated, "During the third quarter we saw continued steady growth of our development pipeline. We announced the advancement of two important programs, the decision to advance BMN 673 for the treatment of gBRCA breast cancer into Phase 3 and the initiation of a Phase 1/2 trial of BMN 190 for the treatment of Batten Disease." Bienaimé continued, "The next major inflection point for the company is the potential market approval of Vimizim in the U.S. and Europe. We have been working diligently to prepare for the launch of this drug and look forward to the Advisory Committee meeting November 19 and potential CHMP opinion, which we expect near the end of the year or early 2014." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN]

--

Dyax Corp. Research Report

On October 22, 2013, Dyax Corp. (Dyax) released its Q3 2013 results. Dyax registered total revenues of $13.7 million in Q3 2013, up 4.5% YoY. The Company posted net loss attributable to common shareholders of $6.2 million or $0.06 per diluted share in Q3 2013, compared to net loss attributable to common shareholders of $5.2 million or $0.05 per diluted share in Q3 2012. Gustav Christensen, President and CEO of Dyax, commented, "Dyax saw a number of important milestones in the third quarter, including growth in the KALBITOR business and successful initiation of the clinical program for DX-2930, a wholly-owned product candidate currently in development for potential prophylactic use in HAE." Christensen added, "Additionally, there were a number of positive Phase 3 data readouts from LFRP candidates, as well as the completion of marketing applications in the U.S. and Europe for one of these candidates, ramucirumab, for second-line advanced gastric cancer." The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/58ae_DYAX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner